2022 年第三季度报告 单位：元 币种：人民币 证券代码：688315 证券简称：诺禾致源 北京诺禾致源科技股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 本报告期 年初至报告 | --- | --- | --- | --- | --- | |------------------------------------------------|----------------|----------------------------------|------------------|----------------------- ...

Financial Performance - The company reported a total revenue of RMB 500 million for the first half of 2022, representing a year-on-year increase of 25%[2]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the first half of 2022, representing a 25% year-over-year growth[21]. - The company's operating revenue for the first half of the year reached ¥849,720,608.78, an increase of 5.99% compared to the same period last year[30]. - Net profit attributable to shareholders decreased by 30.50% to ¥56,696,573.09, primarily due to reduced input VAT credits and increased sales and management expenses[30]. - The basic and diluted earnings per share were both ¥0.14, down 36.36% year-on-year, influenced by decreased other income and increased expenses[30]. - The net cash flow from operating activities was -¥19,075,287.48, an improvement from -¥111,111,060.98 in the previous year, mainly due to increased customer payments and tax refunds[30]. - The company's cash and cash equivalents decreased by 32.64% to RMB 604,830,842.10, down from RMB 897,844,459.92 at the end of the previous year[97]. - The company achieved operating revenue of 849.72 million yuan, a year-on-year increase of 5.99%[80]. - The cost of goods sold was RMB 490,975,213.17, reflecting a slight increase of 1.00% from RMB 486,110,561.37 year-on-year[92]. - Sales expenses rose significantly by 26.20% to RMB 158,139,247.54, up from RMB 125,310,449.03, primarily due to increased personnel compensation and marketing expenses[92]. - Management expenses increased by 41.00% to RMB 89,992,628.52, compared to RMB 63,826,789.60 in the previous year, driven by higher salaries and consulting fees[92]. User Growth and Market Expansion - User data showed an increase in active users by 15%, reaching a total of 1.2 million users by the end of June 2022[2]. - User data showed a 30% increase in active users, reaching 500,000 by the end of the reporting period[21]. - The company expects a revenue growth of 30% for the second half of 2022, driven by new product launches and market expansion strategies[2]. - Market expansion plans include entering three new international markets by Q4 2022, aiming for a 10% market share in each[21]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2023[2]. Research and Development - Investment in R&D increased by 20% compared to the previous year, focusing on innovative technologies in genetic testing[2]. - The company is investing heavily in R&D, with a budget increase of 15% compared to the previous year, focusing on genomic technologies[21]. - The R&D expenditure accounted for 6.58% of operating revenue, a slight decrease of 0.02 percentage points compared to the same period last year[30]. - The company’s R&D investment reached CNY 55.88 million, a year-on-year increase of 5.61%, with R&D expenses accounting for 6.58% of revenue, a slight decrease of 0.02 percentage points[56]. - The company has developed 45 patents related to gene sequencing technology and 274 software copyrights, covering various research areas including molecular mechanisms of diseases and genetic diversity[39]. - The company has developed a series of technical reserves in complex sequencing technologies, including transcriptomics and regulatory genomics, to expand the application scenarios of new technologies[53]. Product Development and Innovation - The company has launched a new product line that is projected to contribute an additional RMB 100 million in revenue by the end of 2022[2]. - New product launches are expected to contribute an additional 200 million RMB in revenue by the end of the year[21]. - The company has developed innovative tumor gene mutation detection kits, becoming one of the first high-throughput tumor gene detection kit manufacturers approved for market in China[56]. - The company has introduced a rapid molecular POCT platform for respiratory pathogen detection, including a novel coronavirus nucleic acid detection kit, which has received EU CE certification[56]. - The company has developed a fully automated production system, enhancing measurement efficiency and stability while reducing costs[50]. Strategic Acquisitions and Partnerships - A strategic acquisition of a local biotech firm is in progress, expected to enhance the company's capabilities in personalized medicine[2]. - The company is exploring potential acquisitions to enhance its technology portfolio, with a target of completing at least one acquisition by the end of 2022[21]. - A new strategic partnership was announced, expected to enhance distribution channels and increase market penetration by 25%[21]. Risk Management and Compliance - The company has identified potential risks related to regulatory changes, which may impact future operations and market strategies[2]. - The company is actively monitoring regulatory changes in the genomics testing industry to ensure compliance and avoid penalties[89]. - The company recognizes the risk of talent shortages as it expands, and is focused on optimizing personnel structure and attracting skilled professionals[89]. - The ongoing global pandemic poses a risk to the company's performance, prompting a push towards digital operations and automation to maintain competitiveness[89]. Environmental and Social Responsibility - The company has implemented measures to reduce carbon emissions, including energy-saving actions and promoting a green office culture[127]. - The company has taken steps to manage waste, including proper disposal of hazardous waste and promoting recycling initiatives[129]. - The company has not reported any environmental violations or issues that would affect its operations[126]. Shareholder Commitments and Governance - The company has committed to long-term promises regarding competition and related transactions, with strict adherence to these commitments[134]. - The company guarantees that all commitments made are true, accurate, and complete, accepting legal responsibility for any misrepresentation[148]. - The company will ensure compliance with the rules set by the China Securities Regulatory Commission regarding share transfer restrictions[154]. - The company will publicly apologize and rectify any breaches of commitments made by its shareholders or executives[148].

Financial Performance - The company's operating revenue for Q1 2022 was ¥386,628,023.16, representing a year-on-year increase of 5.83%[6] - The net profit attributable to shareholders of the listed company was ¥18,866,423.65, a decrease of 42.66% compared to the same period last year[6] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥12,381,188.53, reflecting a slight increase of 2.30% year-on-year[6] - Basic and diluted earnings per share were both ¥0.05, down 44.44% year-on-year[9] - Net profit for Q1 2022 was CNY 20,012,365.86, a decrease of 40.8% from CNY 33,619,210.00 in Q1 2021[39] - Operating profit for Q1 2022 was CNY 22,255,507.84, down 41.5% from CNY 37,916,476.22 in Q1 2021[37] - Total comprehensive income for Q1 2022 was CNY 16,743,883.58, down from CNY 35,621,664.65 in Q1 2021[39] Cash Flow - The net cash flow from operating activities was -¥186,140,305.10, indicating a significant cash outflow[9] - Cash flow from operating activities for Q1 2022 was negative CNY 186,140,305.10, compared to negative CNY 139,732,903.79 in Q1 2021[44] - The net cash flow from investing activities was -$44.34 million, a decrease from $80.12 million in the previous period[46] - Cash inflow from financing activities totaled $52 million, compared to $12 million in the prior period[46] - The net cash flow from financing activities was -$4.29 million, a significant improvement from -$42.87 million previously[46] - The net decrease in cash and cash equivalents was -$240.82 million, worsening from -$103.28 million in the previous period[46] - The ending balance of cash and cash equivalents was $650.15 million, down from $890.98 million at the beginning of the period[46] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,747,597,284.93, a decrease of 3.91% from the end of the previous year[9] - Current assets totaled approximately ¥1.74 trillion, down from ¥1.91 trillion, indicating a decrease of around 8.9%[32] - Cash and cash equivalents were reported at ¥651.55 million, a significant drop from ¥897.84 million, representing a decline of approximately 27.4%[29] - Accounts receivable increased to ¥578.95 million from ¥527.59 million, marking an increase of about 9.7%[29] - Total liabilities were approximately ¥929.57 million, down from ¥1.06 billion, reflecting a decrease of about 12.4%[34] - Shareholders' equity totaled approximately ¥1.82 billion, an increase from ¥1.80 billion, indicating a growth of about 1.4%[34] Research and Development - Research and development expenses totaled ¥25,549,842.88, which is 6.61% of operating revenue, down by 1.04 percentage points year-on-year[9] - Research and development expenses for Q1 2022 were CNY 21,864,425.24, a decrease of 22% from CNY 27,956,011.94 in Q1 2021[37] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 6,256[17] - The company reported a total of ¥6,485,235.12 in non-recurring gains and losses for the period[10]

Financial Performance - The company achieved operating revenue of RMB 1,866,396,324.39, representing a year-on-year growth of 25.26%[130]. - Net profit attributable to shareholders reached RMB 22,498,610, representing a significant increase of 515.74% year-on-year[130]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 17,560,390, reflecting a remarkable growth of 696.11%[130]. - The company's total assets reached CNY 285,935,190, marking a year-on-year growth of 41.22%[130]. - The net assets attributable to shareholders increased to CNY 179,181,010, a growth of 60.52% year-on-year[130]. - The net cash flow from operating activities was CNY 29,347,370, showing a decrease of 14.21% compared to the previous year[130]. - The company plans to distribute a cash dividend of RMB 0.06 per share, totaling RMB 24,012,000, which represents 10.67% of the net profit attributable to shareholders[7]. - The company's operating revenue for 2021 was CNY 1,866,396,324.39, representing a year-on-year increase of 25.26%[38]. - The net profit attributable to shareholders for 2021 was CNY 224,986,098.35, a significant increase of 515.74% compared to the previous year[38]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 175,603,907.22, up 696.11% year-on-year[38]. Research and Development - The company is investing RMB 200 million in R&D for new technologies, focusing on genomic sequencing advancements[21]. - Research and development investment totaled RMB 150.41 million, reflecting a year-on-year increase of 33.91%[48]. - The R&D expenditure as a percentage of operating revenue was 8.06%, up from 7.54% in the previous year[38]. - The number of R&D personnel increased to 443, accounting for 20.42% of the total workforce, reflecting a focus on innovation[113]. - The company is developing a new product for transcription regulation and 3D genome analysis, with an expected total investment of CNY 87.90 million[96]. - The company is working on an automated bioinformatics workflow project to improve project delivery efficiency and reduce human error[96]. - The company aims to optimize the cost of second-generation sequencing sample preparation and library construction through high-performance automation[96]. - The company has developed a targeted gene detection kit for lung cancer, which has received regulatory approval for three medical device categories, focusing on genes such as EGFR, ALK, and KRAS[7]. Market Expansion and Strategy - The company provided guidance for the next quarter, expecting revenue to be between RMB 1.6 billion and RMB 1.8 billion, indicating a growth rate of 20% to 30%[21]. - Market expansion plans include entering three new international markets by the end of the fiscal year, targeting a 10% increase in overall market share[21]. - The company is actively expanding its product line into IVD, genetics, and pathogen detection, aiming to mitigate risks associated with a single service offering[120]. - The company plans to deepen its global business layout by establishing localized laboratories and enhancing its service network, with a goal to increase its international brand recognition and market penetration[184]. - The company is targeting the clinical testing market, which is still in its early stages, by leveraging its proprietary gene mutation detection kits and expanding its product offerings[184]. Compliance and Governance - The company has received a standard unqualified audit report from its accounting firm[6]. - The board of directors has confirmed the accuracy and completeness of the annual report[4]. - The company has not reported any significant risks that could materially affect its operations during the reporting period[5]. - The company has not faced any violations of decision-making procedures regarding external guarantees[10]. - The company has not reported any special arrangements for corporate governance[8]. - The company emphasizes the importance of risk awareness regarding forward-looking statements in the report[9]. - The company adheres to strict governance practices, ensuring compliance with relevant laws and regulations while maintaining transparency in its operations[190]. - The company’s governance structure meets the requirements set by the China Securities Regulatory Commission, ensuring the protection of shareholder rights and interests[193]. Innovation and Technology - The company has established a leading gene sequencing platform with high-throughput sequencing technology and bioinformatics analysis, providing multi-level research services and solutions for life sciences and clinical applications[52]. - The company has developed over 10 personalized targeted metabolomics methods and projects, and launched 4D proteomics products to meet diverse customer needs in proteomics[51]. - The company has successfully automated the pre-treatment production line for mass spectrometry, expanding automation applications to multi-omics business areas, enhancing efficiency and capacity[51]. - The company has developed a comprehensive multi-omics integration research technology platform, expanding its capabilities in proteomics and metabolomics, with targeted metabolomics achieving high sensitivity and accuracy[86]. - The company has launched an online information collection system to improve operational efficiency and establish a comprehensive global information management matrix[51]. - The company has achieved a DNA extraction success rate of 93.28%, RNA extraction success rate of 88.97%, and microbial extraction amplification success rate of 98.58%[81]. - The company has developed innovative tumor gene detection medical devices based on core gene sequencing technology, actively expanding into multiple sectors including IVD, genetics, and pathogens[78]. Customer and Market Insights - User data showed a 30% increase in active users, reaching 2 million by the end of the quarter[21]. - The company has established a global technical service network, covering approximately 70 countries and regions, and serving over 5,900 clients, including top research institutions[54]. - The company primarily serves research institutions, hospitals, and pharmaceutical companies, utilizing a direct sales model to engage clients[60]. - The company has established a stable long-term partnership with qualified suppliers, ensuring product quality and supply capabilities[58]. - The company has a global market presence, serving over 5,900 clients across approximately 70 countries, with significant contributions from overseas technology service business[114]. Risks and Challenges - The company faces risks related to product and service singularity, as it currently lacks clinical application qualifications in certain areas, which could impact its competitive edge[120]. - The company acknowledges the risk of intense market competition leading to potential price declines, and it plans to enhance service quality and operational efficiency to maintain competitiveness[121]. - The company is increasing supplier diversity to reduce reliance on major suppliers like Illumina and Thermo Fisher, addressing supply chain risks[121]. - The company is expanding its overseas operations while ensuring compliance with local laws and regulations to mitigate operational risks in international markets[121].

Financial Performance - The company's operating revenue for Q3 2021 was ¥474,266,282.44, representing a year-over-year increase of 28.48%[7] - The net profit attributable to shareholders for Q3 2021 was ¥47,478,898.42, reflecting a significant increase of 105.75% compared to the same period last year[7] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2021 was ¥39,912,560.35, up 94.18% year-over-year[7] - Total operating revenue for the first three quarters of 2021 reached ¥1,275,995,770.26, a 33.7% increase from ¥954,285,378.45 in the same period of 2020[34] - Net profit for the third quarter of 2021 was ¥131,029,348.76, a significant recovery from a net loss of ¥55,564,509.15 in the same quarter of 2020[34] - The total comprehensive income for the third quarter of 2021 was ¥125,556,224.37, compared to a loss of ¥56,533,496.23 in the same quarter of 2020[34] - Basic and diluted earnings per share for the first three quarters of 2021 were CNY 0.34, compared to a loss of CNY 0.15 in the same period of 2020[40] Research and Development - Research and development (R&D) expenses totaled ¥45,116,002.74 for Q3 2021, an increase of 65.25% compared to the same period last year[11] - R&D expenses accounted for 9.51% of operating revenue in Q3 2021, an increase of 2.11 percentage points year-over-year[11] - Research and development expenses for the third quarter of 2021 were ¥95,349,213.00, up from ¥78,702,531.64 in the same quarter of 2020, indicating a 21.1% increase[34] - The company is focused on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[30] Assets and Liabilities - Total assets at the end of Q3 2021 were ¥2,523,474,560.67, a 24.63% increase from the end of the previous year[11] - The company's total assets reached ¥2,523,474,560.67, up from ¥2,024,732,082.96 in the previous year[34] - Accounts receivable increased significantly to RMB 433,697,035.44 from RMB 321,999,155.20, reflecting a growth of approximately 34.7% year-over-year[26] - The company's inventory also saw an increase, rising to RMB 260,309,304.39 from RMB 201,581,129.33, which is a growth of around 29.1%[26] - Total current liabilities decreased to RMB 779,352,409.10 from RMB 897,478,042.40, showing a reduction of approximately 13.2%[29] - The company's total liabilities amounted to ¥815,302,474.89, down from ¥903,855,566.28 in the previous year[34] - The company's long-term equity investments remained stable at RMB 23,333,615.04, unchanged from the previous year[29] - The company’s total liabilities decreased, indicating improved financial health and stability[29] Cash Flow - The company reported a net cash flow from operating activities of -¥42,937,286.65 for the year-to-date period[11] - Cash inflow from operating activities totaled CNY 1,176,218,057.77, an increase from CNY 1,089,193,214.42 year-over-year[40] - Net cash outflow from operating activities was CNY -42,937,286.65, slightly worse than CNY -41,235,843.06 in the previous year[40] - Cash inflow from investment activities was CNY 827,809,806.35, up from CNY 473,712,687.54 in the same period last year[42] - Net cash outflow from investment activities was CNY -291,235,754.49, compared to a net inflow of CNY 40,292,203.88 in the previous year[42] - Cash inflow from financing activities was CNY 488,781,961.60, compared to CNY 276,118,796.66 in the same period last year[42] - Net cash inflow from financing activities was CNY 404,601,483.16, significantly higher than CNY 9,208,013.77 in the previous year[42] - The ending cash and cash equivalents balance was CNY 510,342,781.55, up from CNY 315,972,017.86 at the end of the previous year[42] Equity - Shareholders' equity attributable to the parent company reached ¥1,702,185,386.64, up 52.49% compared to the previous year[11] - The equity attributable to shareholders of the parent company increased to ¥1,702,185,386.64 from ¥1,116,250,391.49, marking a 52.4% growth[34] - Total equity remained stable at 1,120,876,516.68, unchanged from the previous period[51]

证券代码：688315 证券简称：诺禾致源 公告编号：2021-031 北京诺禾致源科技股份有限公司 关于参加北京辖区上市公司投资者集体接待日的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 为进一步加强与广大投资者的沟通交流，北京诺禾致源科技股份有限公司（以 下简称"公司"）将参加"2021 年北京辖区上市公司投资者集体接待日"活动，现 将有关事项公告如下： 本次集体接待日活动将采取网络远程的方式举行，投资者可以登录"上证路 演中心"网站（http://roadshow.sseinfo.com）或关注微信公众号上证路演中心， 参与本次投资者集体接待日活动，活动时间为 2021 年 9 月 23 日（星期四）15:00 至 17:00。 届时公司的董事会秘书王其锋和财务总监施加山将通过网络在线交流形式与 投资者就公司治理、发展战略、经营状况、股权激励和可持续发展等投资者关注 的问题进行沟通。 欢迎广大投资者积极参与。 特此公告。 北京诺禾致源科技股份有限公司董事会 2021 年 9 月 11 日 1 ...

Financial Performance - The company reported a revenue of 1.2 billion RMB for the first half of 2021, representing a year-over-year growth of 30%[1]. - The company expects a revenue guidance of 2.5 billion RMB for the full year 2021, indicating a growth target of 20%[1]. - The company reported a revenue of RMB 300 million for the first half of 2021, representing a year-on-year increase of 25%[20]. - The company's operating revenue for the first half of 2021 was RMB 801.73 million, representing a 37.02% increase compared to RMB 585.14 million in the same period last year[32]. - Net profit attributable to shareholders was RMB 81.58 million, a significant recovery from a loss of RMB 75.32 million in the previous year[32]. - The company achieved a revenue of approximately ¥415.21 million, with a net profit of around ¥307.38 million, reflecting a strong performance in the first half of 2021[94]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion in the first half of 2021, representing a year-over-year growth of 25%[174]. User Growth - User data indicates an increase in active users by 25% compared to the same period last year, reaching 500,000 active users[1]. - User data showed a growth in active users by 15% compared to the previous year, reaching a total of 1.5 million active users[20]. - User data showed a total of 10 million active users, an increase of 15% compared to the previous year[174]. Research and Development - Research and development expenses increased by 10% to 150 million RMB, focusing on innovative genomic technologies[1]. - Investment in R&D increased by 30% year-on-year, focusing on the development of new technologies and products in the genomic testing sector[20]. - The total R&D investment for the period reached ¥52,912,343.77, an increase of 2.94% compared to the previous period[73]. - The company’s R&D expenses for the current period were ¥51,604,661.95, a slight increase of 0.40% from the previous period[73]. - The company has obtained 37 patents related to gene sequencing technology and 225 software copyrights, demonstrating its strong innovation capabilities[40]. - The company has developed a standardized transcriptome and regulatory group data analysis method, shortening delivery times and expanding application ranges[60]. Market Expansion - The company is expanding its market presence in Southeast Asia, targeting a 15% market share by the end of 2022[1]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2022[20]. - Market expansion plans include entering three new international markets by Q3 2021, aiming for a 10% market share in each[174]. Product Development - New product launches include a next-generation sequencing platform expected to enhance processing speed by 40%[1]. - A new product line is set to launch in Q3 2021, anticipated to contribute an additional RMB 50 million in revenue[20]. - The company is developing a high-throughput newborn genetic disease screening product based on the Illumina sequencing platform, covering over 900 genes and significantly improving screening efficiency[5]. - The company has launched innovative tumor gene mutation detection kits, approved as innovative medical devices by NMPA[65]. Financial Health - The company's total assets increased by 22.06% to RMB 2.47 billion from RMB 2.02 billion at the end of the previous year[32]. - The net assets attributable to shareholders rose by 47.36% to RMB 1.64 billion compared to RMB 1.12 billion at the end of the previous year[32]. - The company reported a net cash flow from operating activities of RMB -111.11 million, an improvement from RMB -181.87 million in the previous year[32]. - The company achieved operating revenue of ¥801,729,487.82, representing a year-on-year growth of 37.02%[105]. Strategic Initiatives - A strategic acquisition of a local biotech firm is expected to enhance the company's capabilities in genetic testing, with a projected completion date in Q4 2021[20]. - The company is exploring partnerships with international research institutions to enhance its product offerings and technological advancements[20]. - The company has initiated a sustainability strategy aimed at reducing operational costs by 15% over the next two years[20]. Governance and Compliance - The board of directors has confirmed the accuracy and completeness of the financial report, ensuring transparency[1]. - The company has not proposed any profit distribution or capital reserve transfer plans for this reporting period[1]. - The company is committed to improving its internal control systems and talent management strategies to address risks related to core technology leakage and personnel turnover[112]. Risk Management - The company faces significant risks in technology development, particularly in the genomic application industry, where failure to develop commercially viable products could adversely affect profitability[110]. - The company is heavily reliant on key suppliers, Illumina and Thermo Fisher, for sequencing instruments and reagents, which poses a risk due to limited supplier diversity[112]. - The company acknowledges the potential impact of ongoing COVID-19 pandemic fluctuations on future performance and is enhancing digital operations to maintain competitiveness[116].

Financial Performance - Operating revenue for the period was CNY 365,313,175.51, representing a year-on-year increase of 64.08%[11] - Net profit attributable to shareholders was CNY 32,905,014.46, a significant recovery from a loss of CNY 62,394,023.64 in the same period last year[11] - Basic earnings per share were CNY 0.09, a recovery from a loss of CNY 0.17 per share in the previous year[11] - Operating profit for Q1 2021 was ¥37,916,476.22, recovering from a loss of ¥64,592,401.88 in Q1 2020[47] - Net profit for Q1 2021 amounted to ¥33,619,210.00, compared to a net loss of ¥63,207,392.64 in the same period last year[47] - The total cost of operations in Q1 2021 was ¥349,964,016.66, up from ¥286,646,888.04 in Q1 2020, reflecting a 22.1% increase[45] - The company reported a tax expense of ¥4,294,920.01 for Q1 2021, compared to a tax benefit of ¥1,795,267.22 in Q1 2020[47] - Other comprehensive income after tax for Q1 2021 was ¥2,002,454.65, up from ¥490,055.87 in Q1 2020[47] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,007,328,739.87, a decrease of 0.86% compared to the end of the previous year[11] - The total current assets decreased to ¥1,119,237,608.85 from ¥1,201,864,828.81, reflecting a reduction in other current assets[29] - Total assets decreased from CNY 2,024,732,082.96 to CNY 2,007,328,739.87, a decline of approximately 0.8%[32] - Current liabilities decreased from CNY 897,478,042.40 to CNY 807,671,119.88, a reduction of about 10%[32] - Total liabilities decreased from CNY 903,855,566.28 to CNY 850,798,497.96, a reduction of approximately 5.9%[34] - The company’s total non-current assets increased from CNY 712,695,154.27 to CNY 712,425,212.36, a slight decrease of about 0.4%[38] - The total liabilities decreased to ¥539,293,226.67 from ¥686,203,389.96 year-over-year, a reduction of approximately 21.5%[40] - The total assets decreased to ¥1,584,757,463.30 from ¥1,729,595,807.47, reflecting a decline of approximately 8.4%[40] Cash Flow - The net cash flow from operating activities improved to CNY -139,732,903.79, compared to CNY -315,651,953.34 in the same period last year[11] - Cash flow from operating activities for Q1 2021 was negative at approximately -¥139.73 million, an improvement from -¥315.65 million in Q1 2020[53] - Cash inflow from operating activities totaled 139,533,644.53 RMB, compared to 102,799,757.35 RMB in the same period last year, representing a 35.7% increase[62] - Cash outflow from operating activities decreased to 302,051,772.62 RMB from 411,103,818.05 RMB, indicating a reduction of approximately 26.5%[62] - The company reported cash inflow from investment activities of approximately ¥240.41 million in Q1 2021, compared to ¥236.35 million in Q1 2020[53] Shareholder Information - The total number of shareholders at the end of the reporting period was not specified, but significant shareholders include Li Ruiqiang with 15.2% ownership[12] - The total equity attributable to shareholders was CNY 1,116,250,391.49, with minority interests at CNY 4,626,125.19[69] - Shareholders' equity totaled CNY 1,043,392,417.51, reflecting an increase in undistributed profits to CNY 215,083,430.92[73] Research and Development - Research and development expenses accounted for 7.65% of operating revenue, down 3.56 percentage points from the previous year[11] - Research and development expenses for Q1 2021 were ¥27,956,011.94, compared to ¥24,947,377.57 in Q1 2020, indicating a 12.1% increase[45] - The company has not disclosed any major new product developments or market expansion strategies in this report[18] Government Support - The company received government subsidies amounting to CNY 15,122,383.55 during the reporting period[14] Other Financial Metrics - The weighted average return on equity increased by 8.83 percentage points to 2.90%[11] - The company reported a significant increase in other income, which reached ¥15,122,383.55, up 1,131.08% from ¥1,228,387.89, primarily due to increased VAT deductions[23] - The investment income increased to ¥578,107.97, a 66.19% rise from ¥347,866.04, due to higher dividends from financial assets[23] - The company’s short-term borrowings decreased by 53.65% to ¥33,030,050.00 from ¥71,262,494.16, indicating repayment of bank loans[20]